Insulin-like growth factor binding proteins and breast cancer

Breast Cancer Research and Treatment

Volumn 107, Issue 2, 2008, Pages 181-194

  Subramanian, Ashok ^a,c   Sharma, Anup ^a   Mokbel, Kefah ^a,b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Breast cancer; Insulin like growth factor; Insulin like growth factor binding protein

Indexed keywords

SOMATOMEDIN BINDING PROTEIN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; BREAST DEVELOPMENT; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; HORMONE ACTION; HUMAN; MITOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL SURVIVAL; EXTRACELLULAR MATRIX; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MAMMARY GLANDS, HUMAN; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 37449012863     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9549-0     Document Type: Review

References (115)

1. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA et al (2006) Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. 1. Endocrinology 147(7):3484-3500
2. Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8(3):197-209
3. Marshman E, Streuli CH (2002) Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4(6):231-239
4. Clemmons DR, Cascieri MA, Camacho-Hubner C, McCusker RH, Bayne ML (1990) Discrete alterations of the insulin-like growth factor I molecule which alter its affinity for insulin-like growth factor-binding proteins result in changes in bioactivity. J Biol Chem 265(21):12210-12216
5. Gershtein ES, Shatskaya VA, Ermilova VD, Kushlinsky NE, Krasil'nikov MA (1999) Phosphatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta 287(1-2):59-67
6. Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP (1996) Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Mol Carcinog 15(3):227-238
7. Zhou X, Tan M, Stone HV, Klos KS, Lan KH, Yang Y et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779-6788
8. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10(23):8059-8067
9. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M et al (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28(5, suppl. 16):125-141
10. Mills GB, Lu Y, Kohn EC (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 98(18):10031-10033
11. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943-1947
12. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155(4):1253-1260
13. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204(1):93-100
14. Janes PW, Daly RJ, deFazio A, Sutherland RL (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9(12):3601-3608
15. Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, Endoh H et al (2000) Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 5(8):593-601
16. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99(7):1478-1483
17. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R et al (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499-506
18. Zhang CC, Shapiro DJ (2000) Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. 2. J Biol Chem 275(1):479-486
19. Kim MS, Lee EJ, Kim HR, Moon A (2003) p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells 46. Cancer Res 63(17):5454-5461
20. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI (2000) Biological and clinical associations of c-jun activation in human breast cancer. 1. Int J Cancer 89(2):177-186
21. Vuori K, Ruoslahti E (1994) Association of insulin receptor substrate-1 with integrins. Science 266(5190):1576-1578
22. Woodward TL, Xie J, Fendrick JL, Haslam SZ (2000) Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulin-like growth factor I, ovarian hormones, and extracellular matrix proteins. 1. Endocrinology 141(10):3578-3586
23. Hovey RC, Mackenzie DD, McFadden TB (1998) The proliferation of mouse mammary epithelial cells in response to specific mitogens is modulated by the mammary fat pad in vitro. In Vitro Cell Dev Biol Anim 34(5):385-392
24. Deeks S, Richards J, Nandi S (1988) Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor. 1. Exp Cell Res 174(2):448-460
25. Shamay A, Cohen N, Niwa M, Gertler A (1988) Effect of insulin-like growth factor I on deoxyribonucleic acid synthesis and galactopoiesis in bovine undifferentiated and lactating mammary tissue in vitro. Endocrinology 123(2):804-809
26. Ruan W, Kleinberg DL (1999) Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140(11):5075-5081
27. Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH (1999) Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol 144(6):1337-1348
28. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM (1996) Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137(1):321-330
29. Moorehead RA, Fata JE, Johnson MB, Khokha R (2001) Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ 8(1):16-29
30. Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, LeRoith D (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97(10):2225-2232
31. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21(6):2203-2212
32. Schwertfeger KL, Richert MM, Anderson SM (2001) Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 15(6):867-881
33. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer 98. Lancet 351(9113):1393-1396
34. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57(4):330-340
35. Renehan AG, Zwahlen M, Minder C, O'dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346-1353
36. Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. 1. Endocr Relat Cancer 13(2):273-278
37. Paik S (1992) Expression of IGF-I and IGF-II mRNA in breast tissue. 8. Breast Cancer Res Treat 22(1):31-38
38. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ et al (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. 2. Mol Endocrinol 3(3):509-517
39. Toropainen EM, Lipponen PK, Syrjanen KJ (1995) Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis. 1. Anticancer Res 15(6B):2669-2674
40. Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. 1. Endocr Rev 20(6):761-787
41. LeRoith D, Baserga R, Helman L, Roberts CT Jr (1995) Insulin-like growth factors and cancer. Ann Intern Med 122(1):54-59
42. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK (2005) Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 41(11):1515-1527
43. Kostecka Y, Blahovec J (1999) Insulin-like growth factor binding proteins and their functions (minireview). 2. Endocr Regul 33(2):90-94
44. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y et al (2004) Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. 2. Cancer Res 64(2):665-671
45. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. 1. Endocr Rev 23(6):824-854
46. Schedlich LJ, Young TF, Firth SM, Baxter RC (1998) Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. 1. J Biol Chem 273(29):18347-18352
47. Reinecke M, Collet C (1998) The phylogeny of the insulin-like growth factors. 1. Int Rev Cytol 183:1-94
48. Forbes BE, Turner D, Hodge SJ, McNeil KA, Forsberg G, Wallace JC (1998) Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain 16. J Biol Chem 273(8):4647-4652
49. Neumann GM, Marinaro JA, Bach LA (1998) Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6. 2. Biochemistry 37(18):6572-6585
50. Coverley JA, Baxter RC (1997) Phosphorylation of insulin-like growth factor binding proteins. 2. Mol Cell Endocrinol 128(1-2):1-5
51. Coverley JA, Baxter RC (1995) Regulation of insulin-like growth factor (IGF) binding protein-3 phosphorylation by IGF-I. 3. Endocrinology 136(12):5778-5781
52. Hashimoto R, Ono M, Fujiwara H, Higashihashi N, Yoshida M, Enjoh-Kimura T et al (1997) Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. 3. J Biol Chem 272(44):27936-27942
53. Lalou C, Lassarre C, Binoux M (1996) A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137(8):3206-3212
54. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y (1999) Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. 1. Endocrinology 140(3):1319-1328
55. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR (1993) Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. 3. Proc Natl Acad Sci USA 90(22):10553-10557
56. Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. 1. Endocr Rev 18(6):801-831
57. Radulescu RT (1994) Nuclear localization signal in insulin-like growth factor-binding protein type 3. 3. Trends Biochem Sci 19(7):278
58. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA (1998) Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. 3. J Invest Dermatol 111(2):239-242
59. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA (1997) Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. 4. Endocrinology 138(4):1763-1766
60. Perks CM, Newcomb PV, Norman MR, Holly JM (1999) Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. 6. J Mol Endocrinol 22(2):141-150
61. Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. 1. J Biol Chem 272(18):12181-12188
62. Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G et al (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. 1. Int J Cancer 83(4):497-505
63. Imai Y, Busby WH Jr, Smith CE, Clarke JB, Garmong AJ, Horwitz GD et al (1997) Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. 2. J Clin Invest 100(10):2596-2605
64. Firth SM, Baxter RC (1999) Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. 4. J Endocrinol 160(3):379-387
65. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR (1991) Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. 1. Proc Natl Acad Sci USA 88(17):7481-7485
66. Nickerson T, Huynh H, Pollak M (1997) Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. 3. Biochem Biophys Res Commun 237(3):690-693
67. Smits VA, Medema RH (2001) Checking out the G(2)/M transition. 3. Biochim Biophys Acta 1519(1-2):1-12
68. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM (2002) A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. 5. Biochem Biophys Res Commun 294(5):988-994
69. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM (1999) Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. 1. J Cell Biochem 75(4):652-664
70. Butt AJ, Firth SM, King MA, Baxter RC (2000) Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. 3. J Biol Chem 275(50):39174-39181
71. Rajah R, Lee KW, Cohen P (2002) Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. 1. Cell Growth Differ 13(4):163-171
72. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D (1993) Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. 6. J Cell Biochem 52(2):196-205
73. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK (1990) Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. 2. Endocrinology 127(6):2679-2686
74. Pekonen F, Nyman T, Ilvesmaki V, Partanen S (1992) Insulin-like growth factor binding proteins in human breast cancer tissue. 1. Cancer Res 52(19):5204-5207
75. Yee D, Favoni RE, Lippman ME, Powell DR (1991) Identification of insulin-like growth factor binding proteins in breast cancer cells. 2. Breast Cancer Res Treat 18(1):3-10
76. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS (1998) Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. 2. Epidemiology 9(5):570-573
77. Bruning PF, Van DJ, Bonfrer JM, Van Noord PA, Korse CM, Linders TC et al (1995) Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. 4. Int J Cancer 62(3):266-270
78. Baxter RC (2001) What is the significance of IGF-binding protein-3 proteolysis in the circulation? 2. J Clin Endocrinol Metab 86(10):5087-5088
79. Oh Y (1998) IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 47(3):283-293
80. Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR, Holly JM (2000) Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. 2. Int J Cancer 88(3):448-453
81. Gill ZP, Perks CM, Newcomb PV, Holly JM (1997) Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. 4. J Biol Chem 272(41):25602-25607
82. Huynh H, Yang X, Pollak M (1996) Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. 5. J Biol Chem 271(2):1016-1021
83. Martin JL, Weenink SM, Baxter RC (2003) Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells: involvement of p44/42 and p38 mitogen-activated protein kinases. 1. J Biol Chem 278(5):2969-2976
84. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC (2004) Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. 1. J Clin Endocrinol Metab 89(4):1950-1956
85. Conover CA (1991) Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3. 1. Endocrinology 129(6):3259-3268
86. Conover CA (1992) Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism 11. Endocrinology 130(6):3191-3199
87. De Mellow JS, Baxter RC (1988) Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. 1. Biochem Biophys Res Commun 156(1):199-204
88. McCaig C, Perks CM, Holly JM (2002) Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. 2. J Cell Sci 115(pt 22):4293-4303
89. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL et al (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression 5. Eur J Cancer 38(18):2362-2370
90. Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR (1993) Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. 4. J Cell Biol 121(3):679-687
91. Oh Y, Muller HL, Lamson G, Rosenfeld RG (1993) Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells: cell surface binding and growth inhibition. J Biol Chem 268(20):14964-14971
92. Martin JL, Ballesteros M, Baxter RC (1992) Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. 1. Endocrinology 131(4):1703-1710
93. Firth SM, Ganeshprasad U, Baxter RC (1998) Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. 2. J Biol Chem 273(5):2631-2638
94. Leal SM, Liu Q, Huang SS, Huang JS (1997) The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. 5. J Biol Chem 272(33):20572-20576
95. Fanayan S, Firth SM, Baxter RC (2002) Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells: relationship to transforming growth factor-beta 1 signaling. 1. J Biol Chem 277(9):7255-7261
96. McCaig C, Fowler CA, Laurence NJ, Lai T, Savage PB, Holly JM et al (2002) Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. Br J Cancer 86(12):1963-1969
97. Butt AJ, Fraley KA, Firth SM, Baxter RC (2002) IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. 1. Endocrinology 143(7):2693-2699
98. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D (1996) Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. 2. J Natl Cancer Inst 88(9):601-606
99. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV et al (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. 1. Clin Cancer Res 3(1):103-109
100. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M et al (2004) Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. 3. Cancer Sci 95(6):496-502
101. McCarthy K, Laban CA, Bustin SA, Ogunkolade BW, Carpenter R, Jenkins PJ (2003) Expression of insulin-like growth factor binding protein-3 (IGFBP-3) is down regulated in breast cancer compared to normal breast tissue. Endocrine Abstracts 2002:4
102. Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y et al (2004) Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100(6):1110-1122
103. Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE (2005) Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. 2. Breast Cancer Res 7(1):R119-R129
104. Kato MV (2000) A secreted tumor-suppressor, mac25, with activin-binding activity. Mol Med 6(2):126-135
105. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK (2003) Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. 1. Cancer Res 63(13):3783-3790
106. St CB, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al (2000) Genes expressed in human tumor endothelium. 3. Science 289(5482):1197-1202
107. Ahmed S, Yamamoto K, Sato Y, Ogawa T, Herrmann A, Higashi S et al (2003) Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/mac25) modulates its biological activity. 9. Biochem Biophys Res Commun 310(2):612-618
108. Kanemitsu N, Kato MV, Miki T, Komatsu S, Okazaki Y, Hayashizaki Y et al (2000) Characterization of the promoter of the murine mac25 gene. Biochem Biophys Res Commun 279(1):251-257
109. Komatsu S, Okazaki Y, Tateno M, Kawai J, Konno H, Kusakabe M et al (2000) Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). 8. Biochem Biophys Res Commun 267(1):109-117
110. Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M et al (1998) Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. 9. Oncogene 16(19):2459-2467
111. Landberg G, Ostlund H, Nielsen NH, Roos G, Emdin S, Burger AM et al (2001) Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. 7. Oncogene 20(27):3497-3505
112. Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM (2003) Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. 9. Anticancer Res 23(3A):2043-2051
113. Swisshelm K, Ryan K, Tsuchiya K, Sager R (1995) Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. 1. Proc Natl Acad Sci USA 92(10):4472-4476
114. Firth SM, Fanayan S, Benn D, Baxter RC (1998) Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. 3. Biochem Biophys Res Commun 246(2):325-329
115. Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K (2002) Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. 1. Cell Growth Differ 13(5):205-213